title: Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes.
abstract: OBJECTIVE
  Biological dose escalation through stereotactic ablative radiotherapy (SABR) holds promise of improved patient convenience, system capacity and tumor control with decreased cost and side effects. The objectives are to report the toxicities, biochemical and pathologic outcomes of this prospective study.
  
  
  METHODS
  A phase I/II study was performed where low risk localized prostate cancer received SABR 35 Gy in 5 fractions, once weekly on standard linear accelerators. Common Terminology Criteria for Adverse Events v3.0 and Radiation Therapy Oncology Group late morbidity scores were used to assess acute and late toxicities, respectively. Biochemical control (BC) was defined by the Phoenix definition.
  
  
  RESULTS
  As of May 2012, 84 patients have completed treatment with a median follow-up of 55 months (range 13-68 months). Median age was 67 years and median PSA was 5.3 ng/ml. The following toxicities were observed: acute grade 3+: 0% gastrointestinal (GI), 1% genitourinary (GU), 0% fatigue; late grade 3+: 1% GI, 1% GU. Ninety-six percent were biopsy negative post-treatment. The 5-year BC was 98%.
  
  
  CONCLUSIONS
  This novel technique employing standard linear accelerators to deliver an extreme hypofractionated schedule of radiotherapy is feasible, well tolerated and shows excellent pathologic and biochemical control.
authors: Department of Radiation Oncology, University of Toronto, Canada. andrew.loblaw@sunnybrook.ca
authors: Andrew
authors: A
authors: Loblaw
authors: Patrick
authors: P
authors: Cheung
authors: Laura
authors: L
authors: D'Alimonte
authors: Andrea
authors: A
authors: Deabreu
authors: Alexandre
authors: A
authors: Mamedov
authors: Liying
authors: L
authors: Zhang
authors: Colin
authors: C
authors: Tang
authors: Harvey
authors: H
authors: Quon
authors: Suneil
authors: S
authors: Jain
authors: Geordi
authors: G
authors: Pang
authors: Robert
authors: R
authors: Nam
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010315:Particle Accelerators; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D011880:Radiotherapy Planning, Computer-Assisted; D016896:Treatment Outcome